【2h】

Nephrogenic Diabetes Insipidus

机译:肾源性尿崩症

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In view of the evidence that the actions of vasopressin are mediated by the release of adenosine 3,5, cyclic monophosphate (`cyclic-AMP'), the effects of this nucleotide were studied in 3 children with nephrogenic diabetes insipidus (NDI) who were insensitive to vasopressin.Intravenous injections of cyclic-AMP reduced urine flow in 2 of the 3 patients, but did not increase urinary osmolality nor the urinary concentrations of sodium, creatinine, and urea. In these respects the antidiuresis differed from that normally produced by vasopressin.The reduction in urine flow produced by cyclic-AMP was probably related to a fall in glomerular filtration rate associated with the prominent circulatory effects of the nucleotide. These effects appear to preclude the use of cyclic-AMP as an antidiuretic agent in the treatment of NDI.
机译:鉴于有证据表明血管加压素的作用是由3,5环一磷酸腺苷('cyclic-AMP')的释放介导的,在3名患有肾原性尿崩症(NDI)的儿童中研究了该核苷酸的作用对血管加压素不敏感。静脉注射环磷酰胺可减少3例患者中的2例尿液流量,但不会增加尿渗透压,也不会增加钠,肌酐和尿素的尿液浓度。在这些方面,抗利尿剂与通常由血管加压素产生的抗利尿剂不同。环-AMP产生的尿流减少可能与肾小球滤过率下降和核苷酸的显着循环作用有关。这些作用似乎排除了将环AMP作为抗利尿剂用于治疗NDI。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号